Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment
Open Access
- 20 September 2016
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 316 (11) , 1211-1212
Abstract
Buprenorphine, a medication effective in treating individuals with opioid use disorders,1 can be prescribed in the United States by addiction specialists or by physicians who complete an 8-hour course and obtain a US Drug Enforcement Administration waiver. Waivered prescribers have been restricted to treating up to 30 patients with an opioid use disorder concurrently; after a year, physicians could request that the limit be increased to 100 patients. Policy makers have prioritized increasing capacity to provide buprenorphine to fight the opioid epidemic but lack adequate information about how to do so effectively. Patient censuses of buprenorphine prescribers were examined to provide information on whether patient limits have been a barrier to buprenorphine treatment.Keywords
This publication has 5 references indexed in Scilit:
- Association between trajectories of buprenorphine treatment and emergency department and in‐patient utilizationAddiction, 2016
- Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid DependenceJAMA Internal Medicine, 2014
- The Physician Clinical Support System-Buprenorphine (PCSS-B): a Novel Project to Expand/Improve Buprenorphine TreatmentJournal of General Internal Medicine, 2010
- Factors affecting willingness to provide buprenorphine treatmentJournal of Substance Abuse Treatment, 2009
- TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction2004